Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Brentuximab Vedotin + Nivolumab for Hodgkin's Lymphoma
Recruiting1 awardPhase 2
Nashville, Tennessee
This trial is testing whether two drugs, brentuximab vedotin and nivolumab, can treat classical Hodgkin lymphoma that has come back. Brentuximab vedotin is a monoclonal antibody that is linked to a toxic agent called vedotin. Nivolumab is an antibody that enhances the immune system. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.